Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut - 210 Activities to Lift Your Consume and Bust Your Stomach
- 3Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- 4Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- 5Portable Installment Answers for Independent ventures
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Manual for Famous Beverages 2024
- Congo declares its latest Ebola outbreak over, after 43 deaths
- Governments take targeted action as fuel prices hit retail
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- South America's Memorable Destinations: A Movement Guide
- Consumer experts: German petrol hikes rule won't bring down prices
